Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Antinausea regimens compared in patients after chemotherapy
May 12th, 2005
An investigational study evaluated the effect of an antiemetic regimen including Emend (aprepitant; Merck & Co., Inc.) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients with that of the standard regimen only. The results were published in the April 18, 2005, Journal of Clinical Oncology. Researchers wrote, "Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide±doxorubicin or epirubicin. Patients were randomly assigned to either an aprepitant [APR] regimen (day 1, APR 125 mg, ondansetron (OND) 8 mg, and dexamethasone 12 mg before chemotherapy...
Source: Women's Health Weekly (2005-05-12)
|
